Skip to main content
. 2024 Jul 31;22(12):1088–1101. doi: 10.1158/1541-7786.MCR-24-0151

Figure 4.

Figure 4.

Combined ATR inhibition with BOLD-100 results in apoptosis in BRAFMT colorectal cancer. A, CTG cell viability assays in BRAFMT colorectal cancer cells co-treated with BOLD-100 and ATR inhibitors (AZD6738, M4344, M6620) for 72 hours. CI values were calculated to evaluate the nature of interaction. B, PARP, cleaved PARP and cleaved caspase-3 (top), and caspase-3/7 activity levels (bottom) in BRAFMT cells co-treated with BOLD-100 and ATR inhibitors for 48 hours. C, HT29 and VACO432 cells were co-treated with BOLD-100 and ATR inhibitors for 48 hours, and apoptosis was assessed using PI or annexin-V/PI staining. The graph indicates the percentage of positive stained cells. D, VACO432 and HT-29 cells were transfected with 10 nmol/L of SC or two different siRNA sequences targeting ATR for 24 hours, followed by treatment with BOLD-100 for 48 hours and apoptosis assessed by WB for PARP, Cleaved PARP (left) and Caspase 3/7 activity assay (right). Expression of pATRT1989, ATR, pCHK1S345, CHK1, pKAP1S824, and KAP was also determined.